83 related articles for article (PubMed ID: 30219043)
1. Kidney donor age of 50 years or above is a risk factor for calcineurin inhibitor-induced nephrotoxicity.
Takada Y; Tanabe T; Sasaki H; Tsujimoto T; Hotta K; Okada K; Shiono Y; Minami K; Tanaka H; Harada H
Clin Transplant; 2024 Jan; 38(1):e15196. PubMed ID: 37975424
[TBL] [Abstract][Full Text] [Related]
2. [Not Available].
Camilo M; Rodolfo T; Carlos B; Paola G; Sandra J; Nancy Y; Diana G; Jorge P; Diego R; Hector R; Carlos A
Nefrologia; 2022 Sep; ():. PubMed ID: 36124061
[TBL] [Abstract][Full Text] [Related]
3. Measurement of the Immunosuppressant Possession Ratio by Transplant Clinical Pharmacists Captures a Non-Adherence Associated With Antibody-Mediated Rejection.
Chambord J; Chauveau B; Djabarouti S; Vignaud J; Taton B; Moreau K; Visentin J; Merville P; Xuereb F; Couzi L
Transpl Int; 2023; 36():11962. PubMed ID: 38089004
[TBL] [Abstract][Full Text] [Related]
4. Benefits of Switching Mycophenolic Acid to Sirolimus on Serological Response after a SARS-CoV-2 Booster Dose among Kidney Transplant Recipients: A Pilot Study.
Banjongjit A; Phirom S; Phannajit J; Jantarabenjakul W; Paitoonpong L; Kittanamongkolchai W; Wattanatorn S; Prasithsirikul W; Eiam-Ong S; Avihingsanon Y; Hansasuta P; Vanichanan J; Townamchai N
Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298550
[TBL] [Abstract][Full Text] [Related]
5. Chronic Kidney Allograft Disease: New Concepts and Opportunities.
Codina S; Manonelles A; Tormo M; Sola A; Cruzado JM
Front Med (Lausanne); 2021; 8():660334. PubMed ID: 34336878
[TBL] [Abstract][Full Text] [Related]
6. Prospective Measures of Adherence by Questionnaire, Low Immunosuppression and Graft Outcome in Kidney Transplantation.
Prezelin-Reydit M; Dubois V; Caillard S; Parissiadis A; Etienne I; Hau F; Albano L; Pourtein M; Barrou B; Taupin JL; Mariat C; Absi L; Vigneau C; Renac V; Guidicelli G; Visentin J; Merville P; Thaunat O; Couzi L
J Clin Med; 2021 May; 10(9):. PubMed ID: 34068497
[TBL] [Abstract][Full Text] [Related]
7. Donor/Recipient HLA Molecular Mismatch Scores Predict Primary Humoral and Cellular Alloimmunity in Kidney Transplantation.
Meneghini M; Crespo E; Niemann M; Torija A; Lloberas N; Pernin V; Fontova P; Melilli E; Favà A; Montero N; Manonelles A; Cruzado JM; Palou E; Martorell J; Grinyó JM; Bestard O
Front Immunol; 2020; 11():623276. PubMed ID: 33776988
[TBL] [Abstract][Full Text] [Related]
8. Impacts of High Intra- and Inter-Individual Variability in Tacrolimus Pharmacokinetics and Fast Tacrolimus Metabolism on Outcomes of Solid Organ Transplant Recipients.
Thongprayoon C; Hansrivijit P; Kovvuru K; Kanduri SR; Bathini T; Pivovarova A; Smith JR; Cheungpasitporn W
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32664531
[TBL] [Abstract][Full Text] [Related]
9. Optimizing Mycophenolic Acid Exposure in Kidney Transplant Recipients: Time for Target Concentration Intervention.
Metz DK; Holford N; Kausman JY; Walker A; Cranswick N; Staatz CE; Barraclough KA; Ierino F
Transplantation; 2019 Oct; 103(10):2012-2030. PubMed ID: 31584924
[TBL] [Abstract][Full Text] [Related]
10. Tacrolimus Variability: A Cause of Donor-Specific Anti-HLA Antibody Formation in Children.
Kaya Aksoy G; Comak E; Koyun M; Akbaş H; Akkaya B; Aydınlı B; Uçar F; Akman S
Eur J Drug Metab Pharmacokinet; 2019 Aug; 44(4):539-548. PubMed ID: 30737655
[TBL] [Abstract][Full Text] [Related]
11. Impact of calcineurin inhibitor-free immunosuppression on de novo donor-specific antibody formation in liver transplant recipients.
Meszaros M; Dubois V; Congy-Jolivet N; Hamada S; Thevenin C; Faure S; Boillot O; Kamar N; Pageaux GP; Del Bello A; Dumortier J
Liver Int; 2022 May; 42(5):1132-1143. PubMed ID: 35184373
[TBL] [Abstract][Full Text] [Related]
12. mTOR inhibitors and risk of chronic antibody-mediated rejection after kidney transplantation: where are we now?
Grimbert P; Thaunat O
Transpl Int; 2017 Jul; 30(7):647-657. PubMed ID: 28445619
[TBL] [Abstract][Full Text] [Related]
13. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C
Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546
[TBL] [Abstract][Full Text] [Related]
14. Impact of reduced exposure to calcineurin inhibitors on the development of de novo DSA: a cohort of non-immunized first kidney graft recipients between 2007 and 2014.
Girerd S; Schikowski J; Girerd N; Duarte K; Busby H; Gambier N; Ladrière M; Kessler M; Frimat L; Aarnink A
BMC Nephrol; 2018 Sep; 19(1):232. PubMed ID: 30219043
[TBL] [Abstract][Full Text] [Related]
15. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.
Perbos E; Juinier E; Guidicelli G; Dromer C; Merville P; Billes MA; Taupin JL; Neau-Cransac M
Clin Transplant; 2014 Sep; 28(9):1054-60. PubMed ID: 25040585
[TBL] [Abstract][Full Text] [Related]
16. Early immunosuppression treatment correlates with later de novo donor-specific antibody development after kidney and pancreas transplantation.
Pelletier RP; Rajab AA; Diez A; DiPaola NR; Bumgardner GL; Elkhammas EA; Henry ML
Clin Transplant; 2015 Dec; 29(12):1119-27. PubMed ID: 26382932
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
